YANKCOM Partnership Invests $341,000 in Amgen Inc. (NASDAQ:AMGN)

YANKCOM Partnership bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,309 shares of the medical research company’s stock, valued at approximately $341,000.

Other large investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in Amgen during the third quarter worth $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter valued at about $29,000. Matrix Trust Co acquired a new stake in Amgen in the 3rd quarter valued at about $36,000. Heck Capital Advisors LLC bought a new position in Amgen during the fourth quarter worth about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen in the third quarter valued at approximately $56,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 6.5 %

Shares of NASDAQ:AMGN opened at $307.81 on Thursday. The stock has a market cap of $165.46 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The business’s 50 day moving average is $271.14 and its 200 day moving average is $303.52. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. On average, sell-side analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.09%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Redburn Partners lowered their target price on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. UBS Group reduced their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.